Related Experiment Video
Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Real-World Impact of a National Funding-Driven Transition Between Automated Insulin Delivery Systems in Pediatric
Max Walker1,2, Amal Thomas2, Hannah Allison1
1Department of Paediatrics and Child Health, University of Otago, Christchurch, New Zealand.
Abstract:
In October 2024, New Zealand's pharmaceutical funding agency (PHARMAC) introduced fully funded access to Tandem t:slim X2 and Ypsomed YpsoPump insulin pumps, alongside Abbott and Dexcom continuous glucose monitoring (CGM). As Medtronic CGM remained unfunded, continued use of Medtronic automated insulin delivery (AID) systems incurred substantial personal cost, prompting prioritized transition to funded alternatives for all pediatric Medtronic users at our center. This retrospective audit evaluated glycemic outcomes 6 months post-transition. Ninety-eight children/adolescents transitioned AID systems; complete 6-month outcome data were available for 79 (mean age 11.6 ± 3.0 years; diabetes duration 4.68 years; pump use duration 2.44 years). Most transitioned to Tandem Control-IQ (n = 66) or YpsoPump with CamAPS FX (n = 11). Mean HbA1c decreased by 0.24% (from 7.14 ± 0.79% to 6.87 ± 0.86%; P = 0.0012), with no episodes of diabetic ketoacidosis or level 3 hypoglycemia. Funding-driven AID transitions can be safely implemented with structured education and follow-up.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Type I Diabetes II: Pathophysiology
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

